Drug Trial Radar · NCT06646276
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
530
Planned (sponsor's estimate)
Start
Feb 25, 2025
Primary completion
Aug 17, 2027
Study completion Jul 14, 2031
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
Conditions
- Extensive-Stage Small Cell Lung Cancer
Interventions
BMS-986489 (Atigotatug+Nivolumab)Biological
Specified dose on specified days
AtezolizumabBiological
Specified dose on specified days
CarboplatinDrug
Specified dose on specified days
EtoposideDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Up to 5 years
Locations
183 sites in 26 countries. Site status is shown where the registry gives one.
Southern Cancer Center, PC
Daphne, Alabama · Recruiting
Local Institution - 0283
Hot Springs, Arkansas · Completed
Florida Cancer Specialists - South
Fort Myers, Florida · Recruiting
Mid Florida Hematology and Oncology Center
Orange City, Florida · Recruiting
Florida Cancer Specialists - North
St. Petersburg, Florida · Recruiting
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital
Marietta, Georgia · Recruiting
Illinois Cancer Care
Peoria, Illinois · Recruiting
Local Institution - 0037
Minneapolis, Minnesota · Withdrawn
University of New Mexico Comprehensive Cancer Center
Albuquerque, New Mexico · Recruiting
Duke Cancer Institute
Durham, North Carolina · Recruiting
Sanford Medical Center
Bismarck, North Dakota · Recruiting
Sanford Fargo Medical Center
Fargo, North Dakota · Recruiting
Oncology Hematology Care
Cincinnati, Ohio · Recruiting
Sanford Cancer Center
Sioux Falls, South Dakota · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology - Central/South Texas
Austin, Texas · Recruiting
Texas Oncology - Northeast Texas
Tyler, Texas · Recruiting
Oncology & Hematology Associates of Southwest Virginia, Inc.
Roanoke, Virginia · Recruiting
Swedish Cancer Institute - Edmonds
Edmonds, Washington · Recruiting
Swedish Medical Center
Seattle, Washington · Recruiting
Local Institution - 0079
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina · Completed
Local Institution - 0077
ABB, Buenos Aires F.D., Argentina · Completed
Local Institution - 0100
Buenos Aires, Buenos Aires F.D., Argentina · Withdrawn
Local Institution - 0080
CABA, Buenos Aires F.D., Argentina · Active not recruiting
Local Institution - 0094
Río Cuarto, Córdoba Province, Argentina · Active not recruiting
Local Institution - 0202
Campbelltown, New South Wales, Australia · Active not recruiting
Local Institution - 0106
Penrith, New South Wales, Australia · Active not recruiting
Local Institution - 0105
Brisbane, Queensland, Australia · Active not recruiting
Local Institution - 0190
Ballarat Central, Victoria, Australia · Completed
Local Institution - 0175
Murdoch, Western Australia, Australia · Active not recruiting
Local Institution - 0252
Linz, Austria · Active not recruiting
Local Institution - 0255
Rankweil, Austria · Active not recruiting
Local Institution - 0253
Graz, Styria, Austria · Active not recruiting
Local Institution - 0251
Wels, Upper Austria, Austria · Completed
Local Institution - 0092
Liège, Belgium · Active not recruiting
Local Institution - 0198
Brussels, Bruxelles-Capitale, Région de, Belgium · Active not recruiting
Local Institution - 0091
Ghent, Oost-Vlaanderen, Belgium · Active not recruiting
Local Institution - 0187
Sint-Niklaas, Oost-Vlaanderen, Belgium · Active not recruiting
Local Institution - 0166
Fortaleza, Ceará, Brazil · Active not recruiting
Local Institution - 0165
Porto Alegre, Rio Grande do Sul, Brazil · Active not recruiting
Showing 40 of 183 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.